Previous close | 232.60 |
Open | 231.90 |
Bid | 225.50 x N/A |
Ask | 237.00 x N/A |
Day's range | 230.10 - 233.40 |
52-week range | 212.30 - 298.40 |
Volume | |
Avg. volume | 894,404 |
Market cap | 196.231B |
Beta (5Y monthly) | 0.18 |
PE ratio (TTM) | 17.79 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.50 (3.99%) |
Ex-dividend date | 16 Mar 2023 |
1y target est | N/A |
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.